Inhibitor Therapeutics, Inc.

PNK:INTI

$0.08 USD

$0.02 (30.72%)

Volume
2
Average Volume
11.17K
Market Capitalization
$13.76M
P/E Ratio
0.59
Dividend Yield
0.00%
Price Target
$
Year High
$0.30
Year Low
$0.01
Payout Ratio
$0.00
Current Ratio
$61.41

Industry, Sector & symbol

Stock Exchange Other OTC
CEO Dr. Francis E. O'Donnell Jr., M.D.
Industry Biotechnology
Sector Healthcare
Current Symbol INTI
CUSIP 45720M105
CIK 0001042418
Web https://www.inhibitortx.com
Phone 888 841 6811
Currency USD
Employees 3
Country US

Liquidity

Debt-to-Equity Ratio 0.00
Payout Ratio 0.00
Current Ratio 61.41
Quick Ratio 60.97
Cash Ratio 60.97

Sales & Book Value

Annual Sales $-
Price / Sales 0.00
Cash Flow 0.06
Price / Cash Flow 1.39
Price / Book 2.13

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $0.0329
Trailing P/E Ratio 0.59
PEG Ratio 0.00
P/E Growth 0.00
Net Income $12.11M
Net Margin 0.00%
Pretax Margin 0.00%
Return on Equity 316.48%
Return on Assets 243.91%

Financials Score

AltmanZ Score -4.17
Piotroski Score 5.00
Working Capital 9.45M
Total Assets 9.61M
Ebit -2.56M
Market Cap 12.95M
Total Liabilities 3.16M

Poll Results

About Inhibitor Therapeutics, Inc. (PNK:INTI) Stock

Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. ...

Frequently Asked Questions

What is the current Inhibitor Therapeutics, Inc. (INTI) stock price?

Inhibitor Therapeutics, Inc.(PNK:INTI) stock price is $0.08 in the last trading session. During the trading session, INTI stock reached the peak price of $0.3 while $0.013 was the lowest point it dropped to. The percentage change in INTI stock occurred in the recent session was 30.72% while the dollar amount for the price change in INTI stock was $0.02.

INTI's industry and sector of operation?

The PNK listed INTI is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of INTI?

Dr. Francis E. O'Donnell Jr., M.D. | Founder, Executive Chairman & Chief Executive Officer
Mr. James A. McNulty CPA | Interim Chief Financial Officer, Treasurer & Secretary
|
|
|

How many employees does INTI have?

Number of INTI employees currently stands at 3. INTI operates from 449 South 12th Street, Tampa, FL 33602, US.

Link for INTI official website?

Official Website of INTI is: https://www.inhibitortx.com

How do I contact INTI?

INTI could be contacted at phone #888 841 6811 and can also be accessed through its website. INTI operates from 449 South 12th Street, Tampa, FL 33602, US.

How many shares of INTI are traded daily?

The average number of INTI shares traded daily for last 3 months was 11.17K.

What is the market cap of INTI currently?

The market value of INTI currently stands at $13.76M with its latest stock price at $0.08